In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, explores the key factors driving the increasing number of partnerships between telehealth and ...
Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial. The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with ...
Talking about ethics isn’t exactly exciting. Leaders don’t usually jump at the chance to emphasize following rules or exceeding standards—it’s much more appealing to focus on growth than on problems.
Approval was based on positive results from the Phase III balance study, where Tryngolza demonstrated a notable placebo-adjusted triglyceride reduction at 12 months. The FDA has approved Ionis ...